| P50 | author | Pierre Tennstedt | Q40045926 |
| P2093 | author name string | Guido Sauter | |
| | Ronald Simon | |
| | Markus Graefen | |
| | Sarah Minner | |
| | Thorsten Schlomm | |
| | Martina Kluth | |
| | Stefan Steurer | |
| | Antje Krohn | |
| | Fabian Freudenthaler | |
| | Melanie Bauer | |
| | Lia Burkhardt | |
| | Silvia Harasimowicz | |
| | Sarah Fuchs | |
| | Maria C Tsourlakis | |
| | Phillip Stahl | |
| | Hueseyin Sirma | |
| P2860 | cites work | The genomic complexity of primary human prostate cancer | Q24617949 |
| | Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 |
| | FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 |
| | Cancer statistics, 2010 | Q27860525 |
| | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 |
| | Oncogene-mediated alterations in chromatin conformation | Q36061468 |
| | Killin is a p53-regulated nuclear inhibitor of DNA synthesis | Q36535351 |
| | Distinct genomic aberrations associated with ERG rearranged prostate cancer | Q37173727 |
| | Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression | Q37383459 |
| | ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. | Q39500478 |
| | Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 |
| | Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN | Q39711051 |
| | Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis | Q41778982 |
| | PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer | Q42473567 |
| | Is PTEN loss associated with clinical outcome measures in human prostate cancer? | Q43249619 |
| | Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens | Q43864003 |
| | Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer | Q45017329 |
| | PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer | Q47919199 |
| | Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. | Q52623792 |
| | Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer | Q57782669 |
| | Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome | Q57790493 |
| | ThePTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion | Q63966367 |
| | Marked heterogeneity of ERG expression in large primary prostate cancers | Q84814749 |
| P433 | issue | 12 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1612-1620 | |
| P577 | publication date | 2014-04-25 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer | |
| P478 | volume | 27 | |